Amgen, Teva Settle Patent Suit Over Neopogen Generic
A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood...To view the full article, register now.
Already a subscriber? Click here to view full article